Principal Financial Group Inc. Sells 9,201 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Principal Financial Group Inc. cut its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 28.8% in the 3rd quarter, Holdings Channel reports. The firm owned 22,740 shares of the biotechnology company’s stock after selling 9,201 shares during the period. Principal Financial Group Inc.’s holdings in OPKO Health were worth $34,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of OPK. Rubric Capital Management LP lifted its position in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after acquiring an additional 876,272 shares in the last quarter. Y.D. More Investments Ltd bought a new position in shares of OPKO Health in the second quarter worth about $1,840,000. PFG Investments LLC boosted its stake in shares of OPKO Health by 10.4% in the 3rd quarter. PFG Investments LLC now owns 1,061,090 shares of the biotechnology company’s stock valued at $1,581,000 after purchasing an additional 100,125 shares in the last quarter. Finally, Clearline Capital LP bought a new stake in shares of OPKO Health during the 3rd quarter valued at approximately $1,083,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Price Performance

OPK stock opened at $1.51 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76. The company has a market capitalization of $1.03 billion, a P/E ratio of -7.95 and a beta of 1.63. The company has a fifty day moving average price of $1.55 and a 200-day moving average price of $1.50.

Analyst Ratings Changes

A number of brokerages have weighed in on OPK. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Thursday, September 26th. Piper Sandler restated an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, November 8th.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost acquired 280,183 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the transaction, the chief executive officer now directly owns 211,512,405 shares in the company, valued at $317,268,607.50. This represents a 0.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 1,304,255 shares of company stock valued at $2,024,605 in the last three months. Insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.